Drugmakers fear rush of European parallel trade

In the wake of European price cuts, pharmaceutical companies fear not only a hit in their revenues, but a fresh surge in so-called "parallel exports"--estimated to account for a tenth of Europe's medicine trade--elsewhere across the E.U., undermining their margins in many larger and richer countries. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.